CLINICAL_TRIALS
trial_result
· 2023-09-22
Clinical Trial Update: Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy [Phase 2, Phase 3]
Summary
A Phase 2/Phase 3 trial evaluating Befizal 200 mg for Leber hereditary optic neuropathy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hôpital Necker-Enfants Malades | Conditions: Safety Issues, Efficacy, Self | Phase 2, Phase 3 | Status: COMPLETED